Coley kept at neutral by Merrill

Merrill Lynch analyst Tom McGahren maintained Coley Pharmaceutical Group Inc. at neutral after the company reported a loss per share of $0.32, modestly narrower than Merrill's estimate of a $0.35 loss per share. Guidance remained the same, a loss of $37 million to $41million for the year, with management expecting to have about $100 million in cash at year-end. Shares of the Wellesley, Mass.-based pharmaceutical company were up 76 cents, or 7.61%, at $10.75 on volume of 71,552 shares versus the three-month running average of 123,031 shares. (Nasdaq: COLY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.